Trabecular meshwork's collagen network formation is inhibited by non-pigmented ciliary epithelium-derived extracellular vesicles.
collagen
extracellular vesicles
non-pigmented ciliary epithelium
open-angle glaucoma
trabecular meshwork
Journal
Journal of cellular and molecular medicine
ISSN: 1582-4934
Titre abrégé: J Cell Mol Med
Pays: England
ID NLM: 101083777
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
revised:
07
02
2021
received:
28
12
2020
accepted:
09
02
2021
pubmed:
2
3
2021
medline:
18
9
2021
entrez:
1
3
2021
Statut:
ppublish
Résumé
The present research aims to determine whether the application of non-pigmented ciliary epithelium cells derived extracellular vesicles to human trabecular meshwork cells affects the formation and secretion of collagen type I to the extracellular matrix formation. Following the extraction of non-pigmented ciliary epithelium derived extracellular vesicles by a precipitation method, their size and concentration were determined using tunable resistive pulse sensing technology. Extracellular vesicles were incubated with trabecular meshwork cells for 3 days. Morphological changes of collagen type I in the extracellular matrix of trabecular meshwork cells were visualized using confocal microscopy and scanning electron microscopy. A Sirius Red assay was used to determine the total amount of collagen. Finally, collagen type I expression levels in the extracellular matrix of trabecular meshwork cells were quantified by cell western analysis. We found that non-pigmented ciliary epithelium extracellular vesicles were very effective at preventing collagen fibres formation by the trabecular meshwork cells, and their secretion to the extracellular matrix was significantly reduced (P < .001). Morphological changes in the extracellular matrix of trabecular meshwork cells were observed. Our study indicates that non-pigmented ciliary epithelium extracellular vesicles can be used to control collagen type I fibrillogenesis in trabecular meshwork cells. These fibrils net-like structure is responsible for remodelling the extracellular matrix. Moreover, we suggest that targeting collagen type I fibril assembly may be a viable treatment for primary open-angle glaucoma abnormal matrix deposition of the extracellular matrix.
Identifiants
pubmed: 33644975
doi: 10.1111/jcmm.16408
pmc: PMC8034463
doi:
Substances chimiques
Collagen Type I
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3339-3347Subventions
Organisme : Israel Science Foundation
ID : 1545/20
Informations de copyright
© 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
Références
Br J Ophthalmol. 1987 Dec;71(12):886-92
pubmed: 3426993
Cell Biochem Funct. 2013 Mar;31(2):166-72
pubmed: 22961668
Invest Ophthalmol Vis Sci. 2015 May;56(5):2993-3003
pubmed: 26024085
Exp Eye Res. 1984 Apr;38(4):423-33
pubmed: 6373335
Exp Eye Res. 2007 May;84(5):832-42
pubmed: 17350618
Exp Eye Res. 2017 Dec;165:7-19
pubmed: 28860021
J Proteomics. 2010 Sep 10;73(10):1907-20
pubmed: 20601276
Open Ophthalmol J. 2010 Sep 03;4:52-9
pubmed: 21293732
Exp Eye Res. 2009 Apr;88(4):683-8
pubmed: 19385040
Histochem Cell Biol. 1999 Oct;112(4):271-6
pubmed: 10550611
Int J Exp Pathol. 2014 Jun;95(3):158-80
pubmed: 24761792
Exp Eye Res. 2015 Mar;132:73-7
pubmed: 25619138
Dev Cell. 2009 Jul;17(1):9-26
pubmed: 19619488
Am J Epidemiol. 1983 Aug;118(2):166-91
pubmed: 6349332
Invest Ophthalmol Vis Sci. 2012 Oct 09;53(11):7043-51
pubmed: 22956608
FASEB J. 2021 Feb;35(2):e21188
pubmed: 33200492
Invest Ophthalmol Vis Sci. 2013 Oct 01;54(10):6456-62
pubmed: 24003087
Matrix Biol. 2013 Mar 11;32(2):74-85
pubmed: 23159731
Sci Rep. 2016 Apr 12;6:23978
pubmed: 27068479
J Extracell Vesicles. 2018 Oct 17;7(1):1528109
pubmed: 30357008
BMJ. 2017 Sep 13;358:j3889
pubmed: 28903935
Cells. 2020 Sep 04;9(9):
pubmed: 32899718
PLoS One. 2017 Feb 27;12(2):e0171153
pubmed: 28241021
Prog Retin Eye Res. 2007 May;26(3):239-62
pubmed: 17321191
Invest Ophthalmol Vis Sci. 2005 Aug;46(8):2848-56
pubmed: 16043859
Biophys J. 2018 Jun 5;114(11):2665-2678
pubmed: 29874616
Cell. 2016 Mar 10;164(6):1226-1232
pubmed: 26967288
Biotechnol Bioeng. 2017 Apr;114(4):915-923
pubmed: 27775151
Curr Protoc Cell Biol. 2006 Apr;Chapter 3:Unit 3.22
pubmed: 18228490
Dig Liver Dis. 2009 Dec;41(12):875-80
pubmed: 19473897
Ophthalmology. 1991 May;98(5):692-700
pubmed: 2062503
Mol Vis. 2009 Nov 28;15:2488-97
pubmed: 19956414
Mol Vis. 2006 Jul 12;12:774-90
pubmed: 16862071
Exp Eye Res. 2004 Mar;78(3):625-31
pubmed: 15106942
J Neurooncol. 2013 May;113(1):1-11
pubmed: 23456661
Sci Rep. 2017 Nov 2;7(1):14951
pubmed: 29097767
Neuromolecular Med. 2018 Jun;20(2):174-204
pubmed: 29572723
Arch Ophthalmol. 2002 Jun;120(6):714-20; discussion 829-30
pubmed: 12049575
Exp Eye Res. 2015 Apr;133:112-25
pubmed: 25819459
Invest Ophthalmol Vis Sci. 1987 Oct;28(10):1655-60
pubmed: 3654139
Analyst. 2016 Aug 07;141(15):4640-6
pubmed: 27229443
Br J Ophthalmol. 2006 Mar;90(3):262-7
pubmed: 16488940
Ophthalmic Res. 2006;38(1):44-8
pubmed: 16276119
J Mol Cell Cardiol. 1995 Jun;27(6):1281-92
pubmed: 8531210
Invest Ophthalmol Vis Sci. 2019 Aug 1;60(10):3613-3624
pubmed: 31433458
Matrix Biol. 2015 May-Jul;44-46:224-31
pubmed: 25599938
J Proteomics. 2011 May 16;74(6):796-804
pubmed: 21362503
JAMA. 2014 May 14;311(18):1901-11
pubmed: 24825645
J Enzyme Inhib Med Chem. 2016;31(sup1):177-183
pubmed: 27028474
Exp Eye Res. 2006 Apr;82(4):545-57
pubmed: 16386733
J Refract Surg. 2008 Sep;24(7):S715-9
pubmed: 18811117
J Cell Mol Med. 2021 Apr;25(7):3339-3347
pubmed: 33644975
J Ocul Pharmacol Ther. 2015 Mar;31(2):63-77
pubmed: 25587905
Invest Ophthalmol Vis Sci. 2018 Mar 1;59(3):1454-1466
pubmed: 29625468
J Cell Mol Med. 2018 Mar;22(3):1992-2000
pubmed: 29411534
Cell Physiol Biochem. 2014;33(4):1215-24
pubmed: 24752241
PLoS One. 2011;6(8):e23899
pubmed: 21909376
Nat Commun. 2015 May 13;6:7164
pubmed: 25968605
J Cell Mol Med. 2020 Apr;24(8):4646-4658
pubmed: 32168427
Arch Ophthalmol. 2002 Jun;120(6):701-13; discussion 829-30
pubmed: 12049574
Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4772-9
pubmed: 14578398
Invest Ophthalmol Vis Sci. 2016 Nov 1;57(14):5984-5995
pubmed: 27820954
Science. 2004 Mar 5;303(5663):1483-7
pubmed: 15001769
Sci Rep. 2017 Apr 11;7(1):812
pubmed: 28400560
Exp Eye Res. 2008 Apr;86(4):543-61
pubmed: 18313051
Cardiovasc Res. 1999 Apr;42(1):27-44
pubmed: 10434993
Exp Cell Res. 2017 Aug 1;357(1):116-123
pubmed: 28526237
J Extracell Vesicles. 2015 Jul 17;4:27031
pubmed: 26194179
Mol Neurobiol. 2012 Aug;46(1):28-40
pubmed: 22396212
J Clin Invest. 2016 Apr 1;126(4):1163-72
pubmed: 26974161